Ascendis Pharma A/S (ASND) Forms $63.81 Double Top; Rbf Capital Has Boosted Its Valeant Pharmaceuticals Intl (VRX) Holding

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Logo

Rbf Capital Llc increased Valeant Pharmaceuticals Intl (VRX) stake by 136.94% reported in 2017Q4 SEC filing. Rbf Capital Llc acquired 208,700 shares as Valeant Pharmaceuticals Intl (VRX)’s stock declined 28.77%. The Rbf Capital Llc holds 361,100 shares with $7.50 million value, up from 152,400 last quarter. Valeant Pharmaceuticals Intl now has $5.99 billion valuation. The stock decreased 0.87% or $0.15 during the last trading session, reaching $17.18. About 4.93M shares traded. Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has risen 42.00% since April 22, 2017 and is uptrending. It has outperformed by 30.45% the S&P500.

Ascendis Pharma A/S (ASND) formed double top with $66.36 target or 4.00% above today’s $63.81 share price. Ascendis Pharma A/S (ASND) has $2.65 billion valuation. The stock decreased 1.85% or $1.2 during the last trading session, reaching $63.81. About 69,924 shares traded. Ascendis Pharma A/S (NASDAQ:ASND) has risen 130.09% since April 22, 2017 and is uptrending. It has outperformed by 118.54% the S&P500.

Rbf Capital Llc decreased First Internet Bancorp (NASDAQ:INBK) stake by 16,900 shares to 13,100 valued at $500,000 in 2017Q4. It also reduced Ctrip Com Intl Ltd (NASDAQ:CTRP) stake by 7,000 shares and now owns 13,000 shares. Jd Com Inc (NASDAQ:JD) was reduced too.

Investors sentiment decreased to 0.97 in 2017 Q4. Its down 0.02, from 0.99 in 2017Q3. It dropped, as 51 investors sold VRX shares while 74 reduced holdings. 54 funds opened positions while 67 raised stakes. 169.66 million shares or 0.12% less from 169.87 million shares in 2017Q3 were reported. State Of Tennessee Treasury Department invested in 257,625 shares. Parametric Portfolio Associate Lc holds 0.03% or 1.29M shares. 148,992 were reported by Chou Assoc Management Incorporated. Raymond James Finance Ser Advsr reported 72,843 shares. Riggs Asset Managment Co reported 0.07% stake. Bruce And Co stated it has 2.7% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). State Street holds 0% or 153,117 shares in its portfolio. Valley Natl Advisers invested 0% of its portfolio in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Rbf Ltd Limited Liability Company holds 0.83% or 361,100 shares. Advsr Preferred Limited Liability reported 0.01% of its portfolio in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). 6.07M are held by Toronto Dominion Bancorporation. Raymond James And Associate reported 75,441 shares. Moreover, Guggenheim Capital has 0% invested in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Commerzbank Aktiengesellschaft Fi holds 660,981 shares. Winfield Assocs reported 55 shares stake.

Since March 8, 2018, it had 3 insider purchases, and 0 sales for $876,370 activity. Another trade for 30,000 shares valued at $481,500 was bought by PAPA JOSEPH C. Shares for $153,400 were bought by DE SCHUTTER RICHARD U on Thursday, March 8. $241,470 worth of stock was bought by Herendeen Paul on Tuesday, March 13.

Among 28 analysts covering Valeant Pharmaceuticals Intl (NYSE:VRX), 7 have Buy rating, 5 Sell and 16 Hold. Therefore 25% are positive. Valeant Pharmaceuticals Intl had 162 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Sector Perform” rating by RBC Capital Markets given on Wednesday, March 16. Stifel Nicolaus maintained the shares of VRX in report on Wednesday, November 11 with “Buy” rating. Deutsche Bank upgraded the stock to “Buy” rating in Monday, March 5 report. The stock of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has “Hold” rating given on Wednesday, January 17 by BTIG Research. H.C. Wainwright maintained Valeant Pharmaceuticals International, Inc. (NYSE:VRX) on Tuesday, January 16 with “Hold” rating. Morgan Stanley maintained Valeant Pharmaceuticals International, Inc. (NYSE:VRX) rating on Wednesday, March 16. Morgan Stanley has “Equal-Weight” rating and $39 target. The stock of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has “Neutral” rating given on Tuesday, March 8 by Mizuho. Cantor Fitzgerald maintained the stock with “Buy” rating in Monday, September 25 report. Scotia Capital maintained Valeant Pharmaceuticals International, Inc. (NYSE:VRX) on Wednesday, October 14 with “Sector Outperform” rating. The rating was reinitiated by IBC on Monday, November 30 with “Sector Perform”.

Among 7 analysts covering Ascendis Pharma (NASDAQ:ASND), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Ascendis Pharma had 22 analyst reports since September 26, 2016 according to SRatingsIntel. The rating was maintained by Credit Suisse with “Outperform” on Friday, September 22. The stock has “Buy” rating by Wedbush on Thursday, September 28. The firm has “Buy” rating by Bank of America given on Friday, November 17. The stock has “Buy” rating by Wells Fargo on Friday, September 22. As per Tuesday, March 20, the company rating was maintained by Credit Suisse. The firm earned “Buy” rating on Thursday, January 25 by Bank of America. As per Wednesday, April 4, the company rating was maintained by Wedbush. Wedbush maintained Ascendis Pharma A/S (NASDAQ:ASND) rating on Friday, September 22. Wedbush has “Buy” rating and $65.0 target. The firm has “Buy” rating given on Monday, September 11 by Wedbush. The rating was maintained by Wedbush with “Outperform” on Friday, March 24.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Institutional Positions Chart

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: